We are thrilled to announce a significant milestone for PL BioScience! In a recent press release, we reveal that we have successfully closed a €7.8 million Series A financing round. This Series A funding marks a pivotal moment in our company’s growth journey. This substantial infusion
The companies agree to a worldwide Human Platelet Lysate (HPL) Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements, including redirection of HPL customers from Macopharma to PL BioScience. PL BioScience GmbH, a German life science company specializing in the production and
Becoming human: GMP-compliant supplements for cell therapy Don't miss our upcoming first webinar and live Q&A hosted by our Field Application Scientist Dr. Silke Isenhardt! Titled "Moving Towards Animal Free Cell Culture Media: Human Platelet Lysate - An Innovative Solution to FBS", register now to learn about
Becoming human: GMP-compliant supplements for cell therapy We were recently interviewed by European biotech media company Labiotech regarding our thoughts on cell culture reagent challenges, and our line of ELAREM™ Human Platelet Lysate (HPL) for cell therapy. The article features thoughts and quotes from CEO &
"How we conduct our research is often just as important as the results of our research" Sustainability and Ethics are wide-reaching, interdisciplinary issues that often fall to the wayside during the process of modern scientific research. We compiled just some of the ways PL BioScience and ELAREM™
